Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Abivax (ABVX) Enterprise Value: 2021-2025

Historic Enterprise Value for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to $409.3 million.

  • Abivax's Enterprise Value fell 29.58% to $409.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$122.9 million, marking a year-over-year decrease of 1282.13%. This contributed to the annual value of $298.5 million for FY2024, which is 23.81% down from last year.
  • Abivax's Enterprise Value amounted to $409.3 million in Q2 2025, which was up 45.45% from $281.4 million recorded in Q1 2025.
  • Over the past 5 years, Abivax's Enterprise Value peaked at $636.6 million during Q1 2024, and registered a low of -$69.4 million during Q4 2021.
  • Over the past 3 years, Abivax's median Enterprise Value value was $400.6 million (recorded in 2023), while the average stood at $433.2 million.
  • Per our database at Business Quant, Abivax's Enterprise Value skyrocketed by 1,524.89% in 2023 and then crashed by 55.79% in 2025.
  • Quarterly analysis of 5 years shows Abivax's Enterprise Value stood at -$69.4 million in 2021, then soared by 60.40% to -$27.5 million in 2022, then spiked by 1,524.89% to $391.8 million in 2023, then decreased by 23.81% to $298.5 million in 2024, then fell by 29.58% to $409.3 million in 2025.
  • Its last three reported values are $409.3 million in Q2 2025, $281.4 million for Q1 2025, and $298.5 million during Q4 2024.